Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (391-400 of 499) with videos related to

Pageof 50
Sort By:
JAMA Oncology|November 24, 2017
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational StatusJulien Taieb, Hampig Raphael Kourie, Jean-François Emile, et al.
Eclinicalmedicine|March 27, 2023
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialTanios Bekaii-Saab, Takuji Okusaka, David Goldstein, et al.
Clinical Colorectal Cancer|December 12, 2022
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C StudyManish A Shah, Takayuki Yoshino, Niall C Tebbutt, et al.
The New England Journal of Medicine|February 11, 2011
Sunitinib malate for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Laetitia Dahan, Jean-Luc Raoul, et al.
Endoscopy|February 15, 2019
Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) GuidelineCesare Hassan, Piotr Tomasz Wysocki, Lorenzo Fuccio, et al.
The Lancet. Oncology|October 26, 2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trialKohei Shitara, Toshihiko Doi, Mikhail Dvorkin, et al.
The New England Journal of Medicine|May 3, 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal CancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
The Lancet. Oncology|April 17, 2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Takayuki Yoshino, Allen Lee Cohn, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialCharles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Neuroendocrinology|January 4, 2005
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotidePhilippe Ruszniewski, Sofia Ish-Shalom, Machteld Wymenga, et al.
Pageof 50

Showing results (391-400 of 499) with videos related to

Sort By:
Pageof 50
JAMA Oncology|November 24, 2017
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational StatusJulien Taieb, Hampig Raphael Kourie, Jean-François Emile, et al.
Eclinicalmedicine|March 27, 2023
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialTanios Bekaii-Saab, Takuji Okusaka, David Goldstein, et al.
Clinical Colorectal Cancer|December 12, 2022
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C StudyManish A Shah, Takayuki Yoshino, Niall C Tebbutt, et al.
The New England Journal of Medicine|February 11, 2011
Sunitinib malate for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Laetitia Dahan, Jean-Luc Raoul, et al.
Endoscopy|February 15, 2019
Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) GuidelineCesare Hassan, Piotr Tomasz Wysocki, Lorenzo Fuccio, et al.
The Lancet. Oncology|October 26, 2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trialKohei Shitara, Toshihiko Doi, Mikhail Dvorkin, et al.
The New England Journal of Medicine|May 3, 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal CancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
The Lancet. Oncology|April 17, 2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Takayuki Yoshino, Allen Lee Cohn, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialCharles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Neuroendocrinology|January 4, 2005
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotidePhilippe Ruszniewski, Sofia Ish-Shalom, Machteld Wymenga, et al.
Pageof 50